Related Experiment Videos
Technology evaluation: transgenic antithrombin III (rhAT-III), Genzyme Transgenics
1College of Pharmacy, Dalhousie University, Halifax, NS B3H-3JS, Canada. pyeung@kilcom1.UCIS.Dal.CA
Current Opinion in Molecular Therapeutics
|March 16, 2001
Summary
AT-III LLC is developing transgenic recombinant human antithrombin III (rhAT-III) for thrombosis treatment. This potential anticoagulant is currently in phase III clinical trials for cardiac surgery patients.
Area of Science:
- Biotechnology
- Pharmacology
- Hematology
Background:
- Thrombosis and sepsis are critical conditions requiring effective anticoagulants.
- Current treatments for thrombosis may have limitations, necessitating novel therapeutic approaches.
Purpose of the Study:
- To evaluate the efficacy and safety of transgenic recombinant human antithrombin III (rhAT-III) as an anticoagulant.
- To assess rhAT-III's potential in managing conditions involving thrombosis, including sepsis and cardiac surgery.
Main Methods:
- AT-III LLC, a Genzyme joint venture, is conducting phase III clinical trials.
- The trials are investigating rhAT-III in patients undergoing elective cardiac surgery, specifically those requiring cardiopulmonary bypass.
Main Results:
- The study is in phase III clinical trials, indicating promising preliminary data.
- The focus is on its role as an anticoagulant in a high-risk surgical setting.
Conclusions:
- rhAT-III shows potential as a novel anticoagulant therapy.
- Further results from ongoing phase III trials are anticipated to confirm its therapeutic value in thrombosis and related disorders.